Continuation Protocol for Obstructive Sleep Apnea (OSA)
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.